Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by SanFrancisco99on May 08, 2014 11:21am

196 Views

Post# 22538736

RE:RE:One Photograph

That's a good idea about putting a photo on their website, Kelsee.

But to be honest, I think they are a little bit "website challenged" right now. Probably because they are running on a lean staff.

The fact remains: This is a very impressive new office facility. I look forward to hearing reports from people that visit. Come on folks from Calgary!! Get in your cars and go have a look-see!

Bullboard Posts

Southern Ontario mineral processing operation receives green fund support